See the DrugPatentWatch profile for vyvanse
Lannett Company has developed a generic version of Vyvanse (lisdexamfetamine dimesylate) capsules [1][2]. This generic formulation is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children six years of age and older [2]. Lannett's generic lisdexamfetamine dimesylate capsules are available in multiple strengths, including 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg [1].
When can generic Vyvanse be sold?
The availability of generic versions of Vyvanse is subject to patent expiries and any related legal challenges [3]. DrugPatentWatch.com tracks patent information and exclusivity periods for drugs, which determine when generic competition can enter the market [4]. For Vyvanse, the original patent and associated exclusivity periods have been a subject of litigation, impacting the timeline for generic availability [3].
What is the difference between brand-name Vyvanse and Lannett's generic version?
The primary difference between brand-name Vyvanse and Lannett's generic version is the manufacturer and, consequently, the inactive ingredients. Both products contain the same active pharmaceutical ingredient, lisdexamfetamine dimesylate, and are therapeutically equivalent [5]. Generic drugs are required to demonstrate bioequivalence to their brand-name counterparts, meaning they deliver the same amount of active ingredient into the bloodstream in the same amount of time [5].
How does lisdexamfetamine work?
Lisdexamfetamine is a prodrug, meaning it is converted into its active form, dextroamphetamine, after ingestion [6]. This conversion process is facilitated by enzymes in the gastrointestinal tract and blood. Once converted to dextroamphetamine, it acts as a central nervous system stimulant that helps to regulate neurotransmitters, such as dopamine and norepinephrine, which are believed to be involved in attention and impulse control [6].
What are the indications for lisdexamfetamine?
Lisdexamfetamine dimesylate is approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged six years and older, as well as in adults [2]. It is also indicated for the treatment of moderate to severe binge-eating disorder in adults [2].
What are the risks associated with lisdexamfetamine?
Lisdexamfetamine carries potential risks, including the potential for abuse and dependence [2]. It can also cause serious cardiovascular events, psychiatric problems, and circulation problems in the extremities [2]. Patients with pre-existing heart conditions may face increased risks [2]. It is crucial for patients to discuss their full medical history with their healthcare provider before starting this medication [2].
Who manufactures Vyvanse?
Vyvanse is manufactured by Takeda Pharmaceuticals [7]. Lannett Company has developed and is manufacturing a generic version of Vyvanse [1][2].
What is the typical cost of generic lisdexamfetamine?
The cost of generic medications is generally lower than their brand-name counterparts. However, exact pricing can vary based on factors such as insurance coverage, pharmacy, and geographic location. Information on specific pricing for Lannett's generic lisdexamfetamine can be obtained from pharmacies or by consulting drug pricing databases.
How does Lannett's generic lisdexamfetamine compare to other ADHD medications?
Lannett's generic lisdexamfetamine is an alternative to other stimulant and non-stimulant medications used to treat ADHD. It is a once-daily oral medication classified as a prodrug, which may offer a different pharmacokinetic profile compared to immediate-release or extended-release amphetamine formulations. Comparisons with other ADHD treatments would involve assessing efficacy, side effect profiles, duration of action, and potential for abuse [6].
---
Sources:
1. Lannett Company, Inc. "Lannett Announces Launch of Generic Lisdexamfetamine Dimesylate Capsules." [Press Release]
2. U.S. Food and Drug Administration. "Prescribing Information for Lisdexamfetamine Dimesylate Capsules."
3. DrugPatentWatch.com. "Vyvanse Patent Information." https://drugpatentwatch.com/drug/vyvanse/
4. DrugPatentWatch.com. "About Us." https://drugpatentwatch.com/about/
5. U.S. Food and Drug Administration. "Generic Drugs: Questions and Answers."
6. National Institute of Mental Health. "Attention-Deficit/Hyperactivity Disorder (ADHD)."
7. Takeda Pharmaceutical Company Limited. "Vyvanse Product Information."